-
-
-
-
-
-
-
Biofrontera locks databases for actinic keratosis and acne studies
-
-
-
-
-
-
-
Biofrontera completes Phase 2b acne trial enrollment for Ameluz gel
-
-
-
-
-
-
-
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
-
-
-
-
-
-
-
Biofrontera Inc. (BFRI) Announces Highly Significant Results In Phase 3 Study Of AmeluzĀ®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma
-
-
-
-
-
-
-
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
-
466,247 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

